[go: up one dir, main page]

MX9702244A - Derivado de 1,2,3,4-tetrahidroquinoxalinadiona. - Google Patents

Derivado de 1,2,3,4-tetrahidroquinoxalinadiona.

Info

Publication number
MX9702244A
MX9702244A MX9702244A MX9702244A MX9702244A MX 9702244 A MX9702244 A MX 9702244A MX 9702244 A MX9702244 A MX 9702244A MX 9702244 A MX9702244 A MX 9702244A MX 9702244 A MX9702244 A MX 9702244A
Authority
MX
Mexico
Prior art keywords
amino
carboxy
lower alkyl
substituted
halogeno
Prior art date
Application number
MX9702244A
Other languages
English (en)
Inventor
-Ichi Jun Shishikur
Hiroshi Inami
Shuichi Sakamoto
Shin-Ichi Tsukamoto
Masao Sadamata
Masamichi Okada
Mitsuo Fujii
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of MX9702244A publication Critical patent/MX9702244A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un derivado de 1,2,3,4-tetrahidroquinoxalinadiona representado por la siguiente formula (I) o sal del mismo, un receptor de NMDA, glicina y/o antagonista de receptor de AMPA o inhibidor de neurotoxicidad de ácido caínico que contiene el derivado o sal. Además, una composicion farmacéutica que comprende dicho compuesto y un vehículo farmacéuticamente aceptable (Ver Formula) en donde los símbolos de la formula anterior representan respectivamente los siguientes significados: X: N, CH, R: un grupo imidazolilo o un grupo dialquilamino inferior, R1: (1) un átomo de halogeno, un grupo nitro, un grupo ciano, un grupo carboxilo, un grupo amino, un grupo mono o dialquilamino inferior, un grupo alcanoilo inferior, un grupo alquiltio inferior, un grupo alquilsulfinilo inferior, un grupo alquilsulfonilo inferior o un grupo carbamoilo; (2) un grupo alquilo inferior o un grupo alcoxilo inferior que se puede substituir por un átomo de halogeno, un grupo carboxilo o un grupo arilo; (3) un grupo feniloxi que se puede substituir por un grupo alcoxicarbonilo inferior o un grupo carboxilo; R2 representa un grupo hidroxilo, un grupo alcoxi inferior, un grupo amino o un grupo mono o dialquilamino inferior; A: un grupo alquileno inferior que puede estar substituido o un grupo representado por la formula -O-B-, y B: un grupo alquileno inferior, con la condicion de que se excluye el caso en donde R, representa un grupo imidazolino, R1 representa ciano, A representa un grupo etileno y R2 representa un grupo hidroxilo.
MX9702244A 1994-09-27 1995-09-25 Derivado de 1,2,3,4-tetrahidroquinoxalinadiona. MX9702244A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23190894 1994-09-27
JP5948295 1995-03-17
PCT/JP1995/001922 WO1996010023A1 (fr) 1994-09-27 1995-09-25 Derive de 1,2,3,4-tetrahydroquinoxalindione

Publications (1)

Publication Number Publication Date
MX9702244A true MX9702244A (es) 1997-06-28

Family

ID=26400527

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702244A MX9702244A (es) 1994-09-27 1995-09-25 Derivado de 1,2,3,4-tetrahidroquinoxalinadiona.

Country Status (16)

Country Link
US (1) US6096743A (es)
EP (1) EP0784054B1 (es)
KR (1) KR100392151B1 (es)
CN (1) CN1067387C (es)
AT (1) ATE209644T1 (es)
CA (1) CA2199468C (es)
DE (1) DE69524246T2 (es)
DK (1) DK0784054T3 (es)
ES (1) ES2168383T3 (es)
HU (1) HU223945B1 (es)
MX (1) MX9702244A (es)
PL (1) PL181532B1 (es)
PT (1) PT784054E (es)
RU (1) RU2149873C1 (es)
UA (1) UA44283C2 (es)
WO (1) WO1996010023A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057304A (en) * 1992-10-26 2000-05-02 Schering Aktiengesellschaft Quinoxaline-phosphonic acid derivatives
DE19519979A1 (de) * 1995-05-24 1996-11-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
EP0980865B1 (en) * 1997-03-14 2003-11-26 Meiji Seika Kaisha Ltd. Physiologically active substance pf1191 and process for producing the same
DE19728326A1 (de) * 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
PL344406A1 (en) * 1998-06-01 2001-11-05 Shionogi & Co Cyanoiminoquinoxaline derivatives
ATE324369T1 (de) 1999-02-15 2006-05-15 Eisai Co Ltd Heterodiazinon-derivate
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6709667B1 (en) 1999-08-23 2004-03-23 Conceptus, Inc. Deployment actuation system for intrafallopian contraception
ATE330941T1 (de) * 2000-01-24 2006-07-15 Neurosearch As Isatinderivate mit neurotropen aktivität
KR100869271B1 (ko) 2000-06-12 2008-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-디하이드로피리딘 화합물 및 그의 용도
ATE440959T1 (de) * 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
CA2440284A1 (en) * 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP4200902B2 (ja) * 2002-03-29 2008-12-24 アステラス製薬株式会社 神経膠芽腫治療剤
JPWO2003087091A1 (ja) * 2002-04-17 2005-08-18 アステラス製薬株式会社 キノキサリンジオン誘導体無水物の新規結晶
WO2004002488A1 (ja) * 2002-06-28 2004-01-08 Yamanouchi Pharmaceutical Co., Ltd. 脳出血治療剤
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
US20060270709A1 (en) * 2005-04-04 2006-11-30 Eisai Co. Ltd. Dihydropyridine compounds and compositions for headaches
WO2007020521A1 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
JP5183302B2 (ja) * 2007-05-29 2013-04-17 参天製薬株式会社 グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４−テトラヒドロキノキサリン誘導体
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
WO2010053757A1 (en) * 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
EP2338492A1 (en) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
WO2020124090A1 (en) 2018-12-14 2020-06-18 Eisai R&D Management Co., Ltd. Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds
US20240398775A1 (en) 2021-09-15 2024-12-05 University Of The Ryukyus Pharmaceutical composition for use in treating cognitive decline or for use in treating overweight or obesity
JPWO2023042888A1 (es) 2021-09-15 2023-03-23

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007847A1 (en) * 1990-11-06 1992-05-14 Yamanouchi Pharmaceutical Co., Ltd. Fused pyrazine derivative
PT101004B (pt) * 1991-10-26 1999-10-29 Schering Ag Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH07165756A (ja) * 1993-12-14 1995-06-27 Yamanouchi Pharmaceut Co Ltd ヒドロキシキノキサリンジオン誘導体
US5654303A (en) * 1995-06-07 1997-08-05 Warner-Lambert Company Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Also Published As

Publication number Publication date
PL181532B1 (pl) 2001-08-31
PL320059A1 (en) 1997-09-01
EP0784054B1 (en) 2001-11-28
RU2149873C1 (ru) 2000-05-27
EP0784054A1 (en) 1997-07-16
ES2168383T3 (es) 2002-06-16
CA2199468C (en) 2006-06-06
DE69524246D1 (de) 2002-01-10
DE69524246T2 (de) 2002-06-27
US6096743A (en) 2000-08-01
ATE209644T1 (de) 2001-12-15
WO1996010023A1 (fr) 1996-04-04
KR970706274A (ko) 1997-11-03
KR100392151B1 (ko) 2003-11-20
EP0784054A4 (en) 1998-01-07
AU684392B2 (en) 1997-12-11
CN1067387C (zh) 2001-06-20
CA2199468A1 (en) 1996-04-04
AU3533795A (en) 1996-04-19
UA44283C2 (uk) 2002-02-15
HUT77442A (hu) 1998-04-28
PT784054E (pt) 2002-05-31
HU223945B1 (hu) 2005-03-29
CN1168670A (zh) 1997-12-24
DK0784054T3 (da) 2002-03-25

Similar Documents

Publication Publication Date Title
MX9702244A (es) Derivado de 1,2,3,4-tetrahidroquinoxalinadiona.
CA2288122A1 (en) Neuropeptide y receptor antagonist
MX9606510A (es) Derivados benzoheterociclicos.
IL142649A0 (en) Azole derivatives
WO2001009103A3 (en) Imidazole antiproliferative agents
AP9801312A0 (en) 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor anatagonist.
FI954746A (fi) Urea- ja amidijohdannaisia ja niiden käyttö solukalvojen kaliumkanavien säätelyyn
EP0638567A4 (en) ADENOSINE INHIBITORS.
HU9601685D0 (en) 4,5-diaryloxazole derivatives
CA2337825A1 (en) Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions
AP9801321A0 (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-h-indole derivatives.
WO2001036425A3 (de) Imidazolverbindungen als phosphodiesterase vii-hemmer
BG104447A (en) Biphenylamidine derivatives
JO2065B1 (en) Tri-azin compounds
HK1044155A1 (en) Bicyclic vasopressin agonists.
CA2244621A1 (en) 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor antagonists
GC0000218A (en) New imidazole derivatives
ES2103222A1 (es) Derivados tioalquiltiocarbacefalosporina.
RS50449B (sr) Supstituisani bisindolilmaleimidi za inhibiciju proliferacije ćelija
IE832664L (en) Penems.
MX9605794A (es) Intermediario para preparar un compuesto farmaceuticamente activo.
AU653019B2 (en) New urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
TW247909B (es)

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: BGREEN LIMITED

MM Annulment or lapse due to non-payment of fees